Stacie Weninger is the President of FBRI, and a Venture Partner with F-Prime. Prior to this position, she was the Senior Director of Science Programs for the Fidelity Foundations. In 2005, Dr. Weninger served as the Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University. From 2001-2005, Dr. Weninger was a Senior Scientist at Cell Press for the journal Neuron. Before joining Cell Press, Dr. Weninger was a postdoctoral research fellow at Children’s Hospital Boston and Harvard Medical School with Dr. Bruce Yankner. She was a Howard Hughes Medical Institute predoctoral fellow in the Program in Neuroscience at Harvard University. While a graduate student and postdoctoral research fellow, Dr. Weninger was actively involved in undergraduate teaching, winning six teaching awards.
Dr. Weninger received a Ph.D. in neuroscience from Harvard University, and a B.S. degree in chemistry with highest honors from the University of North Carolina, Chapel Hill. She currently chairs the Collaboration for Alzheimer’s Prevention; serves as CEO and Chairman of the Board of Directors for Rugen Therapeutics; serves as a member of the Board of Directors for Aratome, Atalanta, Engrail, Tenvie Therapeutics and Target ALS; serves as a member of the External Advisory Board for Boston Children’s Hospital’s Rosamund Stone Zander Translational Neuroscience Center; serves as a member of the Scientific Advisory Boards for the Breuer Foundation, Brown University’s Carney Center for Alzheimer’s Disease Research, Denali Therapeutics, the Indian Institute of Science’s Centre for Brain Research, the MIT Yang-Tan Center for Molecular Therapeutics, Boston Children’s Hospital Technology Development Fund, the Harvard Blavatnik Biomedical Accelerator Fund, the Tufts Launchpad Accelerator, the UK Dementia Research Institute, MJFF T2T Governing Board, and is part of the Harvard Experts in Residence (XIR) network. She served as the President of Alzforum for over a decade and continues as a special advisor to the site. She was a founding member of the Board of Directors for Denali Therapeutics (NASDAQ: DNLI) and Neumora Therapeutics (NASDAQ: NMRA); as well as a member of the Board of Directors for Annexon Biosciences (NASDAQ: ANNX), BRI-Alzan (acquired by MeiraGTx), Digital Cognition Technologies (acquired by Linus Health), Enspectra, Inscopix (acquired by Bruker Corporation), Sironax, and Syllable Life Sciences (acquired by Neumora).